Pfizer

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

News

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential blockbuster.

News

Ex-CDER chief Cavazzoni rejoins Pfizer as CMO

In a move that will raise eyebrows in Washington, Pfizer has hired former FDA director Patricia Cavazzoni as its new chief medical officer.

News

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

Pfizer's weight-loss aspirations are dealt a heavy blow

Alnylam joins three-way contest in ATTR cardiomyopathy

Pfizer's new drug data in breast cancer draws muted response

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

Ex-CDER chief Cavazzoni rejoins Pfizer as CMO

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks